Compugen Ltd (CGEN) Stock Price, Quote & News

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 765 8585

Fax: 972 3 765 8555

Website: cgen.com

Address:

Azrieli Center, Building D 26 Harokmim Street, Holon, Israel

HuntingBenjmins Nov. 10 at 3:55 PM

$CGEN They certainly know how to manage their money. Looks like they did use the ATM a little which would explain some things. Solid till late 2027 on cash not even considering anything else that may come in.

0 · Reply

TwitteringTom Nov. 10 at 1:50 PM

$CGEN anyone listening? whats the deets? WHEN MOON?

1 · Reply

bowlerhatsftw Nov. 9 at 3:55 PM

$CGEN CGEN

0 · Reply

Sobo90 Nov. 5 at 9:16 PM

$CGEN patience will be tested with this one. Has the right ingredients but the stove is on in a different kitchen.

0 · Reply

TwitteringTom Nov. 4 at 4:55 PM

$CGEN what we getting on monday? anything of substance?

1 · Reply

TwitteringTom Oct. 31 at 7:40 PM

$CGEN FAKE PRICE MOVEMENT?!

1 · Reply

Otus Oct. 28 at 7:00 PM

$CGEN anemic volume!! No interest in buying or selling. Too bad the company is managed by scientists, a real ceo would be pounding the table to every analyst and hedge fund that will listen.

1 · Reply

TwitteringTom Oct. 27 at 3:47 PM

$CGEN what we going to get a big nothing nov 10 earnings?

0 · Reply

Urik Oct. 25 at 5:39 PM

$CGEN great technical setup 🔝🔝

0 · Reply

TwitteringTom Oct. 24 at 7:34 PM

$CGEN what we got a fake news friday pop

0 · Reply

Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:00 AM EST - 5 days ago

Compugen Reports Third Quarter 2025 Results

Nov 4, 2025, 7:00 AM EST - 11 days ago

Compugen to Participate in Stifel 2025 Healthcare Conference

Oct 27, 2025, 7:00 AM EDT - 19 days ago

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Oct 13, 2025, 7:00 AM EDT - 4 weeks ago

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Oct 6, 2025, 7:00 AM EDT - 5 weeks ago

Compugen to Present at SITC 2025

Sep 8, 2025, 7:00 AM EDT - 2 months ago

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 8, 2025, 5:13 AM EDT - 3 months ago

Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

Aug 7, 2025, 6:30 AM EDT - 3 months ago

Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 3 months ago

Compugen Reports Second Quarter 2025 Results

Jul 28, 2025, 7:00 AM EDT - 3 months ago

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Jul 23, 2025, 7:00 AM EDT - 4 months ago

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Jul 21, 2025, 7:00 AM EDT - 4 months ago

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Jun 12, 2025, 7:00 AM EDT - 5 months ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

May 19, 2025, 10:21 AM EDT - 6 months ago

Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript

May 19, 2025, 7:00 AM EDT - 6 months ago

Compugen Reports First Quarter 2025 Results

May 13, 2025, 7:00 AM EDT - 6 months ago

Compugen Announces Leadership Transitions Effective September 2025

May 5, 2025, 7:00 AM EDT - 6 months ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Mar 26, 2025, 7:00 AM EDT - 8 months ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 4, 2025, 10:34 AM EST - 9 months ago

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 7:00 AM EST - 9 months ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 3, 2025, 7:00 AM EST - 9 months ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 9 months ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 18, 2025, 7:00 AM EST - 9 months ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 18, 2025, 6:11 AM EST - 9 months ago

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Feb 4, 2025, 7:00 AM EST - 10 months ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 11 months ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Nov 27, 2024, 7:00 AM EST - 1 year ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 12, 2024, 3:35 PM EST - 1 year ago

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Third Quarter 2024 Results

Nov 11, 2024, 7:00 AM EST - 1 year ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 5, 2024, 9:00 AM EST - 1 year ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data at SITC 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Single Cell Genomics 2024 Conference

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 10, 2024, 5:54 AM EDT - 1 year ago

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports Second Quarter 2024 Results

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jun 17, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Upcoming Antibody Industrial Symposium

May 30, 2024, 7:00 AM EDT - 1 year ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

May 20, 2024, 12:22 PM EDT - 1 year ago

Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript

May 20, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports First Quarter 2024 Results

May 16, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 15, 2024, 7:00 AM EDT - 1 year ago

Compugen Appoints David Silberman as Chief Financial Officer

May 6, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

HuntingBenjmins Nov. 10 at 3:55 PM

0 · Reply

TwitteringTom Nov. 10 at 1:50 PM

$CGEN anyone listening? whats the deets? WHEN MOON?

1 · Reply

bowlerhatsftw Nov. 9 at 3:55 PM

$CGEN CGEN

0 · Reply

Sobo90 Nov. 5 at 9:16 PM

$CGEN patience will be tested with this one. Has the right ingredients but the stove is on in a different kitchen.

0 · Reply

TwitteringTom Nov. 4 at 4:55 PM

$CGEN what we getting on monday? anything of substance?

1 · Reply

TwitteringTom Oct. 31 at 7:40 PM

$CGEN FAKE PRICE MOVEMENT?!

1 · Reply

Otus Oct. 28 at 7:00 PM

$CGEN anemic volume!! No interest in buying or selling. Too bad the company is managed by scientists, a real ceo would be pounding the table to every analyst and hedge fund that will listen.

1 · Reply

TwitteringTom Oct. 27 at 3:47 PM

$CGEN what we going to get a big nothing nov 10 earnings?

0 · Reply

Urik Oct. 25 at 5:39 PM

$CGEN great technical setup 🔝🔝

0 · Reply

TwitteringTom Oct. 24 at 7:34 PM

$CGEN what we got a fake news friday pop

0 · Reply

LarryYMB Oct. 24 at 1:27 PM

$CGEN my new avadel got up to 30k shares, lets go!

3 · Reply

TwitteringTom Oct. 22 at 4:45 PM

$CGEN Oh man all that ESMO data was be hitting the market...LOL.... i just do not get why this wont move

1 · Reply

Ghrr Oct. 22 at 4:12 PM

$CGEN This stock should be well north of $2. I have faith thst it will get to $5 but not sure it will be in my lifetime...lol

0 · Reply

Otus Oct. 21 at 1:58 PM

$CGEN we went from a piece dividend to a piece of poo in a blink.

2 · Reply

TwitteringTom Oct. 21 at 1:56 PM

$CGEN that was fun for the minute lol

0 · Reply

HuntingBenjmins Oct. 21 at 2:57 AM

$CGEN I’d expect a good run here once that ESMO data sinks in.

0 · Reply

TwitteringTom Oct. 14 at 7:54 PM

$CGEN this volume and pricing going to disappear in a few sessions>

0 · Reply

TwitteringTom Oct. 14 at 3:43 PM

$CGEN wellll that was somewhat fun

0 · Reply

Albbro Oct. 13 at 9:35 PM

$CGEN to what do we owe this jump today?

2 · Reply

HuntingBenjmins Oct. 13 at 6:34 PM

$CGEN wow nice!

2 · Reply

_www_larval_com_ Oct. 13 at 6:28 PM

$CGEN just popped 6% higher to 27% (~876Kv) a moment ago, 10/17 options, follow for more volatility.

0 · Reply

DARKP00L Oct. 13 at 4:46 PM

$CGEN the market is buzzing about this stock. Expect possible price changes!

0 · Reply

Market Cap	147.24M
Revenue (ttm)	27.86M
Net Income (ttm)	-14.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-51.08%
Debt to Equity Ratio	0.00

Volume	195,700
Avg Vol	428,544
Day's Range	N/A - N/A
Shares Out	89.24M
Stochastic %K	40%
Beta	2.59
Analysts	Strong Sell
Price Target	$6.25